EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

P079 | THE ROLE OF GUT MICROBIOTA IN MIGRAINE SUBJECTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES: RESULTS THE SPHERA PROJECT

Confinia Cephalalgica · 03.11.2026 · 36 (s1)

DOI: 10.4081/cc.2026.16035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gut microbiota plays an important role in the pathophysiology of different neurological disorders via the gut-brain axis. Approximately 40% of migraine subjects do not achieve a meaningful benefit with anti-CGRP monoclonal antibodies (mAbs). We hypothesized that gut microbiota composition may differ between Responders and Non-Responders to mAbs and serve as one of the determinants of therapeutic outcome.

Methods

We enrolled 93 individuals treated with mAbs (age 41.2 ± 13.3 years) 82.9% females, with 15.0 ± 6.8 monthly migraine days (MMDs) at baseline and a previous failure of 3.1±1.3 preventive medication classes. Responders were defined as subjects achieving at least 50% reduction in MMDs after a 3-moth treatment with mAbs. Fecal samples were collected before mAbs treatment and analyzed by means of 16S rRNA gene sequencing, followed by the evaluation of alpha and beta diversities and the application of the ANCOM-BC2 statistical approach.

Results

After a 3-month treatment period with mAbs, 48 participants qualified as Responders and 45 as Non-Responders. Regarding overall microbial diversity, no differences were observed between the two groups, with comparable alpha-diversity and beta-diversity profiles. However, the ANCOM-BC2 approach demonstrated specific alteration between Responders and Non-Responders in gut microbiota composition at both the genus and species levels. Specifically, at the species level, Responder subjects exhibited a significantly higher abundance of Coprococcus eutactus (LogFC 1.89, p < 0.001), Marseilla massiliensis (LogFC 2.15, p < 0.001), Paraprevotella xylaniphila (LogFC 2.08, p < 0.001), Parasutterella secunda (LogFC 1.95, p < 0.001), Clostridium carnis (LogFC 1.43, p = 0.001). Conversely, Responder subjects showed a lower abundance of Rikenellaceae (LogFC -3.45, p < 0.001), Megamonas rupellensis (LogFC -2.24, p < 0.001), Coriobacteriia (LogFC -1.41, p < 0.001), Megasphaera massiliensis (LogFC -2.08, p < 0.001).

Conclusions

Future mAbs Responders exhibited a distinct microbiota composition associated with an anti-inflammatory profile, featuring a significant enrichment of butyrate-producing bacteria; by contrast, Non-Responders were characterized by a predominantly pro-inflammatory intestinal microbiome. These differences suggest that gut microbiota may act as a biological regulator capable of modulating the therapeutic response. Targeted interventions aimed at restoring intestinal eubiosis may represent a strategy to enhance the clinical response to mAbs.

Zitieren

APA

(2026). P079 | THE ROLE OF GUT MICROBIOTA IN MIGRAINE SUBJECTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES: RESULTS THE SPHERA PROJECT. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.16035

Vancouver

P079 | THE ROLE OF GUT MICROBIOTA IN MIGRAINE SUBJECTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES: RESULTS THE SPHERA PROJECT. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.16035

BibTeX
@article{euvimed2026,
  title = {P079 | THE ROLE OF GUT MICROBIOTA IN MIGRAINE SUBJECTS TREATED WITH ANTI-CGRP MONOCLONAL ANTIBODIES: RESULTS THE SPHERA PROJECT},
  journal = {Confinia Cephalalgica},
  year = {2026},
  volume = {36},
  number = {s1},
  doi = {10.4081/cc.2026.16035}
}
Kostenlos starten →